ABUS News and Press, Arbutus Biopharma Corporation From 03/02/23

Arbutus Biopharma Corporation (ABUS) Q4 2022 Earnings Conference Call March 02, 2023, 08:45 AM ET Company Participants Lisa Caperelli - VP of IR William Collier - President and CEI Michael Sofia - Chief Scientific Officer David Hastings - CFO Michael McElhaugh ...

Arbutus Biopharma press release ( NASDAQ: ABUS ): Q4 GAAP EPS of -$0.46 misses by $0.33 . Revenue of $39M (+254.5% Y/Y) beats by $32.88M . As of December 31, 2022, we had cash, cash equivalents and investments in marketable securities of $184.3 million as compared...

Significant progress made advancing proprietary programs in chronic HBV and Coronavirus AB-729 data from multiple Phase 2a combination clinical trials expected in 2023 Initial Phase 1 data for oral PD-L1, AB-101, and oral RNA Destabilizer, AB-161, expected in the second half of ...

Arbutus Biopharma ( NASDAQ: ABUS ) is scheduled to announce FY earnings results on Thursday, March 2nd, before market open. The consensus EPS Estimate is -$0.45 (+45.8% Y/Y) and the consensus Revenue Estimate is $38.63M (+251.2% Y/Y). Over the last 3 months, EPS estimates have...

Summary Arbutus Biopharma Corp. has $191 million cash giving a runway of less than 3 quarters. ABUS stock has been reporting net losses since 2013; in 2022, the net loss per share was $0.12. It maintains low financial leverage with a debt-to-equity ratio of around 0.015. My intr...

WARMINSTER, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its four...

WARMINSTER, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus management te...

WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that Tram Tran, MD has notifie...

Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into Phase 1 clinical trials in 2023 Strong financial position; cash runway into Q4 2...

Preliminary data from lead-in phase further validates AB-729’s capacity to reduce HBsAg Initial data from IFN phase expected in the first half of 2023 WARMINSTER, Pa., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharma...